Primary Myelofibrosis Pmf clinical trials

Explore recruiting primary myelofibrosis pmf clinical trials.

Recruiting primary myelofibrosis pmf studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Myelofibrosis Pmf trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

Italy, Bulgaria, Denmark, Spain, Poland, Belgium +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Germany, Czechia, Spain, Poland, Italy, Croatia +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

HOVON 172 MF: A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial

Germany, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), Or Post Essential Thrombocythemia MF (Post ET MF) Who Have a Suboptimal Response to Ruxolitinib

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis.

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

France

Phase II and Phase III (Integrated) EU CTIS Study details

Primary Myelofibrosis Pmf trials by city

Primary Myelofibrosis Pmf in Toronto Primary Myelofibrosis Pmf in Vancouver Primary Myelofibrosis Pmf in Montreal Primary Myelofibrosis Pmf in Calgary Primary Myelofibrosis Pmf in Edmonton Primary Myelofibrosis Pmf in Ottawa Primary Myelofibrosis Pmf in Winnipeg Primary Myelofibrosis Pmf in Quebec City Primary Myelofibrosis Pmf in Hamilton Primary Myelofibrosis Pmf in Kitchener Primary Myelofibrosis Pmf in London Primary Myelofibrosis Pmf in Halifax Primary Myelofibrosis Pmf in New York Primary Myelofibrosis Pmf in Los Angeles Primary Myelofibrosis Pmf in Chicago Primary Myelofibrosis Pmf in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease